Teduglutide — clinical evidence
Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.
§3Clinical evidence
§3.1Inflammatory bowel disease and mucosal barrier disorders
Anchor outcome. Clinical remission.
Effect as recorded. Response defined as ≥20 % reduction in parenteral support volume in 63 % versus 30 % with placebo at 24 weeks; difference 33 percentage points (95 % CI 16 to 49).[1,2]
Certainty. Moderate certainty The indication is short-bowel syndrome with intestinal failure, not inflammatory bowel disease; the Institute maps it to the mucosal-barrier indication group for indexing purposes and states the distinction explicitly.
Contributing trials. STEPS · STEPS-2 · TED-PAEDIATRIC. Full structured abstracts are published for each.
Full evidence extract for inflammatory bowel disease and mucosal barrier disorders · Indication assessment
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001 · PMID 29617641
- Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 2019;30:72–130. doi:10.1016/j.molmet.2019.09.010 · PMID 31767182
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.